Sermorelin 5 mg

Buy Sermorelin 5mg Peptides from Adapt Peptides. We are a trusted peptides supplier dedicated to delivering research-grade peptides with over 99% purity levels. Every 5mg Sermorelin vial is backed by independent third-party testing to verify purity levels. Adapt Peptides is known for consistent batch-to-batch quality, reliable U.S. shipping, and responsive customer support, making us a dependable choice for researchers seeking consistent results.

What Is Sermorelin?

Sermorelin (GHRH 1-29) is a synthetic research peptide designed as an analog of growth hormone–releasing hormone (GHRH).

This synthetic, truncated version includes the first 29 amino acids of the naturally occurring GHRH sequence, which is sufficient to maintain its full biological activity in stimulating the pituitary gland to release growth hormone (GH) in experimental models.

Because of this, sermorelin quickly became of interest in both clinical and research settings as a more practical alternative to using full-length GHRH.

Sermorelin was first developed in the late 1970s and 1980s as a diagnostic agent for growth hormone deficiency. Serono Laboratories was one of the sermorelin pioneers and marketed it under the trade name Geref®. The compound was first approved for clinical use in children but has since come off patent, meaning the base peptide is now in the public domain [1].

While the branded product was discontinued, sermorelin remains available today in injectable form through compounding pharmacies and peptide research suppliers. It is still being studied for its ability to stimulate natural GH release rather than replace it directly.

In particular, preclinical research models investigate sermorelin’s ability to influence GH secretion, support recovery and tissue regeneration, and regulate certain metabolic pathways. 

Researchers value the synthetic sermorelin’s short half-life, which allows for controlled studies on pulsatile GH release, a key aspect of endocrine rhythm exploration.

Sermorelin is also widely regarded for its high solubility in common peptide solvents, stability when stored under recommended conditions, and specific action on GHRH receptors with minimal off-target effects.

Sermorelin Mechanism of Action (Based on Research)

Sermorelin (GHRH 1-29) is a synthetic analog of endogenous growth hormone–releasing hormone (GHRH). By replicating the biologically active portion of the native 44–amino acid sequence, it provides a reliable tool for exploring growth hormone (GH) regulation and related physiological pathways.

Although not approved for therapeutic use, Sermorelin has been extensively studied in laboratory settings for its role in modulating the GH axis.

Stimulation of Endogenous Growth Hormone Release

Sermorelin binds to GHRH receptors on pituitary somatotrophs, activating a G-protein–coupled receptor (GPCR) cascade [2]. This process elevates intracellular cAMP and calcium concentrations, ultimately leading to the synthesis and pulsatile secretion of growth hormone (GH) [3].

Unlike exogenous recombinant GH, which bypasses the body’s regulatory loops, Sermorelin’s natural GH release in a pulsatile fashion maintains physiologic feedback through somatostatin and IGF-1. This makes it a valuable compound for investigating hypothalamic–pituitary signaling in research models of both youth and aging.

Indirect Promotion of IGF-1 Production

The GH surge triggered by Sermorelin drives hepatic synthesis of insulin-like growth factor 1 (IGF-1), an essential mediator of anabolic growth pathways. IGF-1 has been linked to processes such as tissue regeneration, cell proliferation, and metabolic regulation [4].

The time delay between GH secretion and IGF-1 elevation provides researchers with an opportunity to examine temporal hormone interactions and downstream effects involving JAK2/STAT5 signaling.

Neuroendocrine Modulation and Circadian Patterns

Research into GHRH analogs suggests potential influences on sleep regulation, though direct studies with Sermorelin remain limited [5]. Evidence indicates that its GH-releasing effects follow circadian rhythms, particularly during early-night slow-wave sleep [6].

Animal and human trials with GHRH analogs, including intranasal formulations, have shown improvements in slow-wave sleep and reduced nighttime cortisol [7]. While Sermorelin-specific data are sparse, existing studies support its role in mimicking natural GH pulsatility and elevating IGF-1 levels, especially in older research populations.

Skeletal Effects and Bone Mineralization

Non-clinical investigations into growth hormone secretagogues (GHS) with mechanisms similar to Sermorelin have demonstrated effects on skeletal health. For instance, ipamorelin-treated female rats displayed increased bone mineral content and cortical bone growth versus controls [8].

Like sermorelin, ipamorelin functions as a growth hormone secretagogue, stimulating endogenous GH release rather than replacing it directly. While sermorelin mimics the structure of GHRH, ipamorelin acts as a selective ghrelin receptor agonist, yet both converge on the same outcome: increased pulsatile growth hormone secretion. That’s why both compounds have been studied in relation to skeletal health, body composition, and metabolic support.

Since Sermorelin works by stimulating endogenous GH release, researchers hypothesize that comparable mechanisms could enhance bone remodeling, mineral deposition, and skeletal integrity in preclinical models.

Sermorelin Research Applications (Sermorelin Benefits)

Sermorelin (GHRH-1-29) is frequently used in laboratory research to examine its effects on the GH/IGF-1 axis and related physiological systems.

Below are some key research areas where sermorelin and related GHRH analogs have provided valuable insights.

Cognitive Function & Brain Health

Controlled clinical studies on GHRH analogs such as tesamorelin (a close structural relative of sermorelin) have reported notable improvements in cognitive performance.

In one trial, older adults—both healthy individuals and those with mild cognitive impairment (MCI)—experienced significant gains in executive function and verbal memory, accompanied by an ~117% increase in circulating IGF-1 levels [9].

These findings suggest that Sermorelin, via GH/IGF-1 signaling, may help researchers investigate pathways involved in neurocognition, memory formation, and even neuroprotection. Its ability to mimic natural pulsatile GH release makes it particularly valuable in studying brain–endocrine connections.

Body Composition & Adiposity

In a six-month study with GHRH analogs, older participants showed a 7.4% reduction in body fat and a 3.7% gain in lean muscle mass, correlating with higher IGF-1 concentrations [9]. While not all trials used Sermorelin directly, its mechanism of stimulating GH release positions it as a strong candidate for exploring similar effects on fat metabolism and muscle development in preclinical research.

Pituitary Responsiveness & Hormonal Profiles

Studies in both healthy adults and elderly men show that nightly Sermorelin administration enhances pulsatile GH release and elevates IGF-1 levels without surpassing physiological limits. In one study, men aged 60–78 receiving 0.5 mg and 1 mg doses effectively doubled their 24-hour GH secretion, with IGF-1 levels restored toward youthful baselines [10].

This suggests Sermorelin is a valuable research tool for modeling age-related changes in pituitary responsiveness and somatotropic axis function.

Endocrine Crosstalk & Metabolic Markers

Beyond its GH/IGF-1 effects, Sermorelin has demonstrated broader endocrine interactions. In children with GH insufficiency, administration temporarily elevated FSH, LH, and prolactin, indicating possible cross-axis signaling [2]

In adult models, Sermorelin has also been observed to enhance insulin sensitivity, supporting its use in research on glucose metabolism and endocrine crosstalk[11].

Skeletal & Bone Markers

Although direct studies on Sermorelin’s impact on bone remain limited, GH secretagogues with similar mechanisms have shown promise in preclinical models. For example, ipamorelin has been linked to increased bone mineral density and cortical bone thickness in animal studies. Because Sermorelin stimulates natural GH release, researchers theorize that it may exert comparable effects on bone remodeling, mineralization, and skeletal health in controlled laboratory environments [8].

Sermorelin Peptide Characteristics

This detailed profile of Sermorelin is drawn from established scientific references and standard product specifications.

• Molecular Formula: C₁₄₉H₂₄₆N₄₄O₄₂S
• CAS Number: 86168-78-7
• Amino Acid Sequence:
  • Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH₂
• Synonyms: Sermorelin, GRF (1-29) Amide, GHRH(1-29) Amide, Geref, Gerel, Human growth hormone–releasing factor fragment (1-29)
• Molar Mass: 3,357.9 Da (free acid form); 3,417.9 Da (acetate salt form)
• Storage Guidelines:
  • Lyophilized peptide should be stored at 2–8 °C for short-term use, or −20 °C for long-term storage in a desiccated vial.
  • After reconstitution, use promptly or aliquot and freeze at −20 °C to minimize degradation.
  • Protect from repeated freeze–thaw cycles, direct heat, and UV exposure.

Sermorelin vs Tesamorelin vs CJC-1295 (Comparison)

Sermorelin Safety and Side Effects in Studies

Preclinical research on Sermorelin (mainly in rodent and other animal models) indicates a generally favorable safety profile when used at standard research doses. Across multiple studies, Sermorelin has been shown to trigger growth hormone (GH) release without causing cytotoxicity or organ-specific damage [10].

Because the peptide has a short half-life and acts specifically through GHRH receptors, it avoids prolonged systemic exposure, which may reduce the likelihood of off-target effects. Within typical experimental ranges, no significant adverse outcomes have been consistently reported.

Animal research suggests that potential side effects are minimal and typically short-lived. Minor local irritation at the site of administration has been noted, but systemic toxicity is rarely observed.

In addition, Sermorelin’s ability to stimulate GH in a pulsatile and physiologic manner—rather than continuously—may represent a relative safety advantage over longer-acting GH analogs. This makes it a practical option for studies focused on endocrine rhythms, feedback loops, and controlled hormone modulation.

Important: Note that there are no conclusive clinical studies establishing sermorelin’s safety profile. At present, it remains strictly a research-use-only compound and is not approved for human or veterinary applications.

Certificate of Analysis (COA)

At Adapt Peptides, every batch of research peptides is independently tested by accredited third-party laboratories to confirm identity, purity, and consistency. Each Sermorelin product is supplied with a Certificate of Analysis (COA), providing documented assurance of quality and reproducibility.

You can usually obtain a COA from the product page, or request a more lot-specific CoA from our support team. This ensures full traceability—an essential requirement for reliable scientific experimentation.

Additionally, we remain open to third-party laboratory testing and verification. If you use any of the sermorelin you purchased for testing, we will refund that vial free of charge. Learn more about this in our FAQ section.

Among other things, these certificates verify:

• Peptide identity (confirmed by mass spectrometry)
• Purity level (analyzed via HPLC)
• Lot number and production date

Legal Disclaimer

Sermorelin is supplied strictly for laboratory research purposes. It is not approved for human or veterinary use.

Not for resale, diagnostic, or therapeutic applications.

All peptides provided by Adapt Peptides are intended for in vitro or experimental use only, by qualified institutions and professionals.

Buyers are responsible for ensuring compliance with local regulations governing the handling and use of research compounds.

Scientific References

1. National Center for Advancing Translational Sciences. (2025). SERMORELIN (Substance: 89243S03TE). In NCATS Inxight: Drugs. U.S. Department of Health & Human Services.

https://drugs.ncats.io/substance/89243S03TE 

2. Halmos G, Szabo Z, Dobos N, Juhasz E, Schally AV. Growth hormone-releasing hormone receptor (GHRH-R) and its signaling. Rev Endocr Metab Disord. 2025 Jun;26(3):343-352.

https://pmc.ncbi.nlm.nih.gov/articles/PMC12137518/ 

3. Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999 Aug;12(2):139-57.

https://pubmed.ncbi.nlm.nih.gov/18031173/ 

4. Laron Z. Insulin-like growth factor 1 (IGF-1): a growth hormone. Mol Pathol. 2001 Oct;54(5):311-6. 

https://pmc.ncbi.nlm.nih.gov/articles/PMC1187088/ 

5. Peterfi Z, McGinty D, Sarai E, Szymusiak R. Growth hormone-releasing hormone activates sleep regulatory neurons of the rat preoptic hypothalamus. Am J Physiol Regul Integr Comp Physiol. 2010 Jan;298(1):R147-56.

https://pmc.ncbi.nlm.nih.gov/articles/PMC2806209/ 

6. Kim TW, Jeong JH, Hong SC. The impact of sleep and circadian disturbance on hormones and metabolism. Int J Endocrinol. 2015;2015:591729.

https://pmc.ncbi.nlm.nih.gov/articles/PMC4377487/ 

7. Perras B, Marshall L, Köhler G, Born J, Fehm HL. Sleep and endocrine changes after intranasal administration of growth hormone-releasing hormone in young and aged humans. Psychoneuroendocrinology. 1999 Oct;24(7):743-57.

https://pubmed.ncbi.nlm.nih.gov/10451909/ 

8. Svensson J, Lall S, Dickson SL, Bengtsson BA, Rømer J, Ahnfelt-Rønne I, Ohlsson C, Jansson JO. The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. J Endocrinol. 2000 Jun;165(3):569-77.

https://pubmed.ncbi.nlm.nih.gov/10828840/ 

9.Baker LD, Barsness SM, Borson S, Merriam GR, Friedman SD, Craft S, Vitiello MV. Effects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol. 2012 Nov;69(11):1420-9.

https://pmc.ncbi.nlm.nih.gov/articles/PMC3764914/ 

10. Sinha DK, Balasubramanian A, Tatem AJ, Rivera-Mirabal J, Yu J, Kovac J, Pastuszak AW, Lipshultz LI. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol. 2020 Mar;9(Suppl 2):S149-S159.

https://pmc.ncbi.nlm.nih.gov/articles/PMC7108996/ 

11. Kim SH, Park MJ. Effects of growth hormone on glucose metabolism and insulin resistance in human. Ann Pediatr Endocrinol Metab. 2017 Sep;22(3):145-152.

https://pmc.ncbi.nlm.nih.gov/articles/PMC5642081/